AUTOBIO DIAGNOSTICS CO., LTD. Financials Autobio Diagnostics Co., Ltd.
Equities
603658
CNE100002GC4
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 56.35 CNY | +0.21% |
|
+3.81% | -1.16% |
| Apr. 19 | Autobio Diagnostics' Q1 Profit Jumps 34% | MT |
| Apr. 19 | Autobio Diagnostics' 2023 Profit Climbs 4% as Operating Income Stays Flat | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 40,480 | 65,473 | 32,280 | 36,261 | 33,123 | 32,712 | - | - |
| Enterprise Value (EV) 1 | 40,480 | 65,473 | 31,721 | 35,240 | 32,335 | 31,649 | 30,972 | 30,141 |
| P/E ratio | 52.4 x | 83.4 x | 33.2 x | 30.9 x | 27.1 x | 22 x | 17.8 x | 14.8 x |
| Yield | 0.93% | 0.59% | 1.31% | 1.29% | 1.84% | 2.28% | 2.51% | 3.28% |
| Capitalization / Revenue | 15.1 x | 22 x | 8.57 x | 8.16 x | 7.45 x | 6.34 x | 5.27 x | 4.61 x |
| EV / Revenue | 15.1 x | 22 x | 8.42 x | 7.93 x | 7.28 x | 6.13 x | 4.99 x | 4.24 x |
| EV / EBITDA | 36 x | 55.5 x | 21.4 x | 20.6 x | 17.7 x | 15.6 x | 12.7 x | 10.6 x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Price to Book | 15.8 x | 10.1 x | 4.44 x | 4.66 x | 3.92 x | 3.44 x | 2.96 x | 2.63 x |
| Nbr of stocks (in thousands) | 546,001 | 586,273 | 586,272 | 586,272 | 581,011 | 580,514 | - | - |
| Reference price 2 | 74.14 | 111.7 | 55.06 | 61.85 | 57.01 | 56.35 | 56.35 | 56.35 |
| Announcement Date | 4/29/20 | 4/22/21 | 3/9/22 | 4/20/23 | 4/18/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2,679 | 2,978 | 3,766 | 4,442 | 4,444 | 5,160 | 6,213 | 7,102 |
| EBITDA 1 | 1,124 | 1,180 | 1,486 | 1,714 | 1,832 | 2,034 | 2,443 | 2,855 |
| EBIT 1 | 894.2 | 856.4 | 1,076 | 1,296 | 1,366 | 1,654 | 2,058 | 2,487 |
| Operating Margin | 33.37% | 28.76% | 28.58% | 29.19% | 30.73% | 32.06% | 33.12% | 35.02% |
| Earnings before Tax (EBT) 1 | 885.7 | 844.5 | 1,066 | 1,294 | 1,363 | 1,679 | 2,073 | 2,493 |
| Net income 1 | 774.2 | 747.8 | 973.7 | 1,167 | 1,217 | 1,504 | 1,859 | 2,229 |
| Net margin | 28.89% | 25.11% | 25.85% | 26.28% | 27.4% | 29.15% | 29.92% | 31.39% |
| EPS 2 | 1.415 | 1.338 | 1.660 | 2.000 | 2.100 | 2.565 | 3.171 | 3.804 |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | 0.6923 | 0.6538 | 0.7200 | 0.8000 | 1.050 | 1.285 | 1.415 | 1.850 |
| Announcement Date | 4/29/20 | 4/22/21 | 3/9/22 | 4/20/23 | 4/18/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,071 | 1,031 | 1,039 | 1,211 | 1,160 | 1,036 | 1,071 | 1,135 | 1,201 | 1,089 | 1,290 | 1,397 | 1,397 | 1,389 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | 266.4 | 284.7 | 327.1 | 413 | 271.6 | 270.9 | 299.5 | 400.5 | 359.3 | 364 | 309.5 | 453.2 | 463.5 | 397.6 |
| Operating Margin | 24.88% | 27.61% | 31.48% | 34.1% | 23.41% | 26.14% | 27.95% | 35.3% | 29.91% | 33.42% | 23.99% | 32.45% | 33.19% | 28.62% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net income | - | - | - | - | - | - | - | - | - | 324.2 | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | 29.77% | - | - | - | - |
| EPS 2 | 0.4400 | 0.4100 | 0.5000 | 0.6300 | 0.4600 | 0.4200 | 0.5200 | 0.6100 | 0.5500 | 0.5600 | 0.5000 | 0.7300 | 0.7300 | 0.6400 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/9/22 | 4/26/22 | 8/17/22 | 10/25/22 | 4/20/23 | 4/20/23 | 8/17/23 | 10/25/23 | 4/18/24 | 4/18/24 | - | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | - | 559 | 1,021 | 788 | 1,063 | 1,740 | 2,571 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | 34.8% | 22.1% | 14.2% | 15.6% | 14.9% | 15.9% | 16.6% | 18% |
| ROA (Net income/ Total Assets) | 22.4% | 12.1% | 11.2% | 11.8% | - | 11.1% | 11.5% | 10.4% |
| Assets 1 | 3,457 | 6,197 | 8,686 | 9,853 | - | 13,602 | 16,134 | 21,432 |
| Book Value Per Share 2 | 4.680 | 11.00 | 12.40 | 13.30 | 14.60 | 16.40 | 19.10 | 21.50 |
| Cash Flow per Share 2 | 1.540 | 1.700 | 2.490 | 2.660 | 2.510 | 2.930 | 3.480 | 4.250 |
| Capex 1 | 761 | 1,115 | 1,066 | 938 | 900 | 751 | 665 | 645 |
| Capex / Sales | 28.41% | 37.43% | 28.29% | 21.12% | 20.25% | 14.54% | 10.71% | 9.08% |
| Announcement Date | 4/29/20 | 4/22/21 | 3/9/22 | 4/20/23 | 4/18/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
56.35
CNY
Average target price
64.39
CNY
Spread / Average Target
+14.26%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -1.16% | 4.51B | |
| +0.89% | 12.8B | |
| -10.29% | 7.61B | |
| +1.78% | 5.41B | |
| +5.74% | 4.49B | |
| -50.70% | 3.29B | |
| +12.21% | 2.73B | |
| -16.13% | 2.02B | |
| -11.50% | 1.73B | |
| -5.02% | 1.64B |
- Stock Market
- Equities
- 603658 Stock
- Financials Autobio Diagnostics Co., Ltd.
